Phase I and Pharmacological Study of the New Topoisomerase I Inhibitor GI147211, Using a Daily X 5 Intravenous Administration

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.1996.130
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Bioavailability and Pharmacokinetics of Oral Topotecan: A New Topoisomerase I Inhibitor

British Journal of Cancer
Cancer ResearchOncology
1996English

A Systematic Study of Nitrated Indenoisoquinolines Reveals a Potent Topoisomerase I Inhibitor

English

Topoisomerase I Inhibition and Cytotoxicity of 5-Bromo- And 5-Phenylterbenzimidazoles

Bioorganic and Medicinal Chemistry
Organic ChemistryMolecular MedicineMolecular BiologyBiochemistryClinical BiochemistryPharmaceutical ScienceDrug Discovery
2000English

Diospyrin, a Bisnaphthoquinone: A Novel Inhibitor of Type I DNA Topoisomerase ofLeishmania Donovani

Molecular Pharmacology
Molecular MedicinePharmacology
1998English

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

Molecular and Cytotoxic Effects of Camptothecin, a Topoisomerase I Inhibitor, on Trypanosomes and Leishmania.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1995English

Intravenous (I. V.) Fluid Administration Systems and Incompatibility of Injection

Yakugaku Zasshi
PharmacologyPharmaceutical Science
1990English

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients With Refractory Hematologic Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2006English

Intrapleural Administration of Interleukin 2 in Pleural Mesothelioma: A Phase I-Ii Study

British Journal of Cancer
Cancer ResearchOncology
1995English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy